T cell responses of 5 Types of COVID-19 vaccines with reported efficacy introduced in Korea
| Platform | Vaccine (Manufacturer) | T cell responses in human |
|---|---|---|
| mRNA | BNT162b2mRNA (BioNTech/Pfizer) | Increases in IFNγ+CD4+/CD8+ T cells after booster vaccination, Predominantly IFNγ and IL-2 secretion |
| mRNA-1273 (Moderna) | Increases in CD4+ T cells secreting TNF > IL-2 > IFNγ after booster vaccination, Low levels of CD8+ T cells activation | |
| Viral vector | ChAdOx1nCoV-19 (Univ. of Oxford & Astra-Zeneca) | Peak T cell responses 14 days after first vaccination, Increase in TNF and IFNγ secretion by CD4+ T cells at day 14 |
| Ad26.COV2.S (Janssen) | Induction of CD4+/CD8+ T cells secreting IFNγ and/or IL-2 at day 14 and 28 days post vaccination | |
| Protein subunit | NVX-CoV2373 (Novavax) | CD4+ T cells responses induced by 7 days after booster vaccination, Production of IFNγ, IL-2 and TNF by CD4+ T cells |
